As of Jan 20
| +0.05 / +2.70%|
The 2 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 5.88, with a high estimate of 6.00 and a low estimate of 5.75. The median estimate represents a +209.21% increase from the last price of 1.90.
The current consensus among 2 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.